cannabis indica

COVID-19

O acervo do Cannabis Indica reúne 119 estudos científicos que tocam a condição COVID-19, publicados entre 1998 e 2024. Pela leitura automatizada, 85 (71%) foram classificados como favoráveis, 22 (18%) como inconclusivos e 12 (10%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (67 estudos), seguido de estudo laboratorial (25). Os compostos mais presentes são Palmitoiletanolamida (PEA), Endocanabinoide (não especificado) e Anandamida (AEA). Aparece com frequência ao lado de Inflamação, Ansiedade e Câncer.

Estudos indexados
119
Período coberto
1998–2024
Favoráveis
85 · 71%
Inconclusivos
22 · 18%
Desfavoráveis
12 · 10%
Termo original
COVID-19

O acervo em números

Tipo de estudo

Metanálise67
Estudo Laboratorial25
Estudo em Animais11
Ensaio Clínico10
Ensaio Clínico Duplo-Cego5
Metanálise Clínica1

Direção do resultado

Favorável85
Inconclusivo22
Desfavorável12

Por década

1990s1
2000s1
2020s117

119 estudos

Filtrar e buscar no acervo →
  1. 2024

    A Single-Blind, Randomized, Placebo Controlled Study to Evaluate the Benefits and Safety of Endourage Targeted Wellness Formula C Sublingual +Drops in People with Post-Acute Coronavirus Disease 2019 Syndrome

    FavorávelEnsaio ClínicoÔmega-3Ômega-6
  2. 2024

    Palmitoylethanolamide and Luteolin for postinfectious olfactory disorders: How clinically meaningful is its effect?

  3. 2023

    Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABAB-ergic activity and cortical plasticity in long COVID-19 syndrome

  4. 2023

    Effect of any form of steroids in comparison with that of other medications on the duration of olfactory dysfunction in patients with COVID-19: A systematic review of randomized trials and quasi-experimental studies

    FavorávelMetanáliseInflamaçãoDepressãoPalmitoiletanolamida (PEA)
  5. 2023

    Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance

    FavorávelMetanáliseCâncerInflamaçãoAnsiedadeCanabigerol (CBG)Canabinol (CBN)+20
  6. 2023

    Involvement of cannabinoid receptors and neuroinflammation in early sepsis: Implications for posttraumatic stress disorder

  7. 2023

    Mental health and substance use screening in HIV primary care before and during the early COVID-19 pandemic

    InconclusivoMetanáliseDependência QuímicaDependência — CannabisAnsiedade+6
  8. 2023

    Moderating the impact of the COVID-19 pandemic on children's and adolescents' substance use, digital media use, and mental health: A randomized positive psychology addiction prevention program

    FavorávelEnsaio ClínicoDependência Química
  9. 2023

    Parosmia COVID-19 Related Treated by a Combination of Olfactory Training and Ultramicronized PEA-LUT: A Prospective Randomized Controlled Trial

  10. 2023

    Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial

    FavorávelEnsaio Clínico Duplo-CegoDoenças NeurodegenerativasPalmitoiletanolamida (PEA)
  11. 2022

    A narrative review of molecular mechanism and therapeutic effect of Cannabidiol (CBD)

    FavorávelMetanáliseDorCâncerInflamação+5
  12. 2022

    Agathis robusta Bark Essential Oil Effectiveness against COVID-19: Chemical Composition, In Silico and In Vitro Approaches

    FavorávelEstudo Laboratorial
  13. 2022

    Anti-Inflammatory and Antiviral Effects of Cannabinoids in Inhibiting and Preventing SARS-CoV-2 Infection

  14. 2022

    Candidate Psychotropics against SARS - CoV - 2: A Narrative Review

    FavorávelMetanálise
  15. 2022

    Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses

    FavorávelEstudo em Animais
  16. 2022

    Cannabinoid hyperemesis syndrome in North America: evaluation of health burden and treatment prevalence

  17. 2022

    Cannabinoids as Emergent Therapy Against COVID-19

  18. 2022

    Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants

    FavorávelEstudo LaboratorialÁcido Canabidiólico (CBD-a)Ácido Canabigerólico (CBG-a)
  19. 2022

    Cannabinoids receptors in Covid-19: Perpetrators and victims

  20. 2022

    Cannabinoids: Therapeutic Use in Clinical Practice

  21. 2022

    Cannabis consumption is associated with lower COVID-19 severity among hospitalized patients: a retrospective cohort analysis

    FavorávelMetanáliseInflamaçãoTetraidrocanabinol (THC)
  22. 2022

    Concurrent use of e-cigarettes and cannabis and associated COVID-19 symptoms, testing, and diagnosis among student e-cigarette users at four U.S. Universities

    DesfavorávelMetanálise
  23. 2022

    Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications

  24. 2022

    Effect of cannabidiol on apoptosis and cellular interferon and interferon-stimulated gene responses to the SARS-CoV-2 genes ORF8, ORF10 and M protein

    FavorávelEstudo Laboratorial
  25. 2022

    Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study

    FavorávelEnsaio ClínicoInflamaçãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  26. 2022

    Effects of non‐steroidal anti‐inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID‐19

  27. 2022

    Endothelial dysfunction and angiogenesis: what is missing from COVID-19 and cannabidiol story?

  28. 2022

    Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic

    FavorávelEnsaio ClínicoAnsiedade
  29. 2022

    Medicinal Herbs in the Relief of Neurological, Cardiovascular, and Respiratory Symptoms after COVID-19 Infection A Literature Review

  30. 2022

    Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial

  31. 2022

    Role of Cannabinoids in Various Diseases: A Review

  32. 2022

    Substance Use Among Youth During the COVID-19 Pandemic: a Systematic Review

  33. 2022

    Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial

    FavorávelEnsaio Clínico Duplo-CegoInflamaçãoPalmitoiletanolamida (PEA)
  34. 2021

    A Cannabinoid 2-Selective Agonist Inhibits Allogeneic Skin Graft Rejection In Vivo

  35. 2021

    A potential role for cannabichromene in modulating TRP channels during acute respiratory distress syndrome

  36. 2021

    A randomized controlled trial of a therapeutic relational agent for reducing substance misuse during the COVID-19 pandemic

    FavorávelEnsaio ClínicoDependência QuímicaDependência — CannabisAnsiedade+2
  37. 2021

    A secondary approach with conventional medicines and supplements to recuperate current COVID-19 status

    FavorávelMetanálise
  38. 2021

    Acute lung injury-from cannabis to COVID

    InconclusivoMetanáliseInflamaçãoEfeitos Adversos da CannabisFibrose+4
  39. 2021

    Adolescent Cannabis Hyperemesis Syndrome During the COVID-19 Pandemic

  40. 2021

    Antimicrobial and Antiviral (SARS-CoV-2) Potential of Cannabinoids and Cannabis sativa: A Comprehensive Review

    FavorávelMetanálise
  41. 2021

    Appropriate use of essential oils and their components in the management of upper respiratory tract symptoms in patients with COVID-19

    FavorávelMetanálise
  42. 2021

    Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches

    FavorávelEstudo Laboratorial
  43. 2021

    Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019

  44. 2021

    Can limonene be a possible candidate for evaluation as an agent or adjuvant against infection, immunity, and inflammation in COVID-19?

    FavorávelMetanálise
  45. 2021

    Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic

  46. 2021

    Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

    InconclusivoEnsaio Clínico Duplo-Cego
  47. 2021

    Cannabidiol Inhibits In Vitro Human Liver Microsomal Metabolism of Remdesivir: A Promising Adjuvant for COVID-19 Treatment

    FavorávelEstudo Laboratorial
  48. 2021

    Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response

  49. 2021

    Cannabidiol inhibits SARS-Cov-2 spike (S) protein-induced cytotoxicity and inflammation through a PPARγ-dependent TLR4/NLRP3/Caspase-1 signaling suppression in Caco-2 cell line

    FavorávelEstudo Laboratorial
  50. 2021

    Cannabinoids as Key Regulators of Inflammasome Signaling: A Current Perspective

    FavorávelMetanáliseInflamaçãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+3
  51. 2021

    Cannabinoids for SARS-CoV-2 and is there evidence of their therapeutic efficacy?

    FavorávelMetanálise
  52. 2021

    Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages

    InconclusivoEstudo LaboratorialInflamaçãoCanabigerol (CBG)Tetraidrocanabivarina (THCV)
  53. 2021

    Cannabis Use among Cancer Survivors amid the COVID-19 Pandemic: Results from the COVID-19 Cannabis Health Study

    InconclusivoEnsaio ClínicoCâncerEpilepsiaInsônia e Distúrbios do Sono+3
  54. 2021

    Cannabis-Induced Mania Following COVID-19 Self-Medication: A Wake-Up Call to Improve Community Awareness

    DesfavorávelMetanáliseEfeitos Adversos da CannabisPsicoseTranstorno Bipolar
  55. 2021

    Cannabis/Cannabinoids for Treating COVID-19 Associated Neuropsychiatric Complications

    InconclusivoMetanáliseDependência — CannabisAnsiedadeDepressão+2
  56. 2021

    Could Cannabidiol Be a Treatment for Coronavirus Disease-19-Related Anxiety Disorders?

    FavorávelMetanáliseAnsiedadeDepressãoInsônia e Distúrbios do Sono+1
  57. 2021

    COVID-19 and Cannabis: Playing Saint or Devil?

  58. 2021

    D-Limonene Is a Potential Monoterpene to Inhibit PI3K/Akt/IKK-α/NF-κB p65 Signaling Pathway in Coronavirus Disease 2019 Pulmonary Fibrosis

    FavorávelEstudo em AnimaisFibroseFibrose — Pulmonar
  59. 2021

    Effect of COVID-19 Pandemic on Cannabis Use in Cancer Patients

    InconclusivoMetanáliseCâncer
  60. 2021

    Electrochemical sensing: A prognostic tool in the fight against COVID-19

    FavorávelMetanáliseInflamação
  61. 2021

    Endocannabinoid Anandamide Attenuates Acute Respiratory Distress Syndrome through Modulation of Microbiome in the Gut-Lung Axis

  62. 2021

    Essential oils as an effective alternative for the treatment of COVID-19: Molecular interaction analysis of protease (Mpro) with pharmacokinetics and toxicological properties

    FavorávelEstudo Laboratorial
  63. 2021

    Fighting the storm: could novel anti-TNFα and anti-IL-6 C. sativa cultivars tame cytokine storm in COVID-19?

    InconclusivoEstudo LaboratorialCanabigerol (CBG)Canabinol (CBN)+2
  64. 2021

    Genetic Liability to Cannabis Use Disorder and COVID-19 Hospitalization

  65. 2021

    High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients

  66. 2021

    Human Laboratory Models of Cannabis Use: Applications for Clinical and Translational Psychiatry Research

    FavorávelMetanáliseDorDependência QuímicaCâncer+16
  67. 2021

    In quest of a new therapeutic approach in COVID-19: the endocannabinoid system

    FavorávelMetanálise
  68. 2021

    In silico identification of compounds from Nigella sativa seed oil as potential inhibitors of SARS-CoV-2 targets

    FavorávelEstudo Laboratorial
  69. 2021

    In silico inquest reveals the efficacy of Cannabis in the treatment of post-Covid-19 related neurodegeneration

    FavorávelEstudo Laboratorial
  70. 2021

    In Vitro Evaluation of the Activity of Terpenes and Cannabidiol against Human Coronavirus E229

    FavorávelEstudo Laboratorial
  71. 2021

    Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021

  72. 2021

    Less COVID-19 deaths in southern and insular Italy explained by forest bathing, Mediterranean environment, and antiviral plant volatile organic compounds

    FavorávelMetanálise
  73. 2021

    Lifestyle Interventions Improving Cannabinoid Tone During COVID-19 Lockdowns May Enhance Compliance With Preventive Regulations and Decrease Psychophysical Health Complications

  74. 2021

    Management of Acute Lung Injury: Palmitoylethanolamide as a New Approach

  75. 2021

    Mechanism deconvolution of Qing Fei Pai Du decoction for treatment of Coronavirus Disease 2019 (COVID-19) by label-free integrative pharmacology assays

    FavorávelEstudo Laboratorial
  76. 2021

    Medicinal Applications of Cannabinoids Extracted from Cannabis sativa (L.): A New Route in the Fight Against COVID-19?

    FavorávelMetanáliseDorCâncerDor — Crônica+5
  77. 2021

    Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation

    FavorávelMetanáliseInflamaçãoPalmitoiletanolamida (PEA)
  78. 2021

    Multiple clinical risks for cannabis users during the COVID-19 pandemic

    DesfavorávelMetanálise
  79. 2021

    Non-Cannabinoid Metabolites of Cannabis sativa L. with Therapeutic Potential

    FavorávelMetanálise
  80. 2021

    Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19

    FavorávelMetanálise
  81. 2021

    Randomized clinical trial "olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin": preliminary results

    FavorávelEnsaio ClínicoPalmitoiletanolamida (PEA)
  82. 2021

    Role of PI3K/Akt axis in mitigating hippocampal ischemia-reperfusion injury via CB1 receptor stimulation by paracetamol and FAAH inhibitor in rat

    FavorávelEstudo em AnimaisAVCAnandamida (AEA)Endocanabinoide (não especificado)+1
  83. 2021

    Structurally modified compounds of hydroxychloroquine, remdesivir and tetrahydrocannabinol against main protease of SARS-CoV-2, a possible hope for COVID-19: Docking and molecular dynamics simulation studies

    FavorávelEstudo Laboratorial
  84. 2021

    Targeting of Protein's Messenger RNA for Viral Replication, Assembly and Release in SARS-CoV-2 Using Whole Genomic Data From South Africa: Therapeutic Potentials of Cannabis Sativa L

    FavorávelEstudo Laboratorial
  85. 2021

    The Immunopathology of COVID-19 and the Cannabis Paradigm

    InconclusivoMetanálise
  86. 2021

    The Link between Cannabis Use, Immune System, and Viral Infections

    DesfavorávelMetanáliseInflamaçãoHIV/AIDSHepatite
  87. 2021

    The potential of cannabinoids and inhibitors of endocannabinoid degradation in respiratory diseases

    FavorávelMetanáliseCâncerCâncer — PulmãoFibrose+2
  88. 2021

    Ultramicronized Palmitoylethanolamide in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation

    FavorávelEstudo em AnimaisInflamaçãoSepsePalmitoiletanolamida (PEA)
  89. 2021

    Unsubstantiated health claims for COVID-19 infections are led by cannabidiol: return of snake oil medicine

    InconclusivoMetanálise
  90. 2021

    What cannabis can learn from Covid: Hydroxychloroquine research suggests the next step for medical cannabis research

    InconclusivoMetanálise
  91. 2021

    WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2

    FavorávelEstudo LaboratorialCanabinoides Sintéticos WIN-x
  92. 2021

    β-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19

    InconclusivoMetanáliseInflamaçãoDoenças Cardiovasculares (DCV)Disfunção Cognitiva+7
  93. 2020

    Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?

    InconclusivoMetanálise
  94. 2020

    Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?

    InconclusivoMetanálise
  95. 2020

    Cannabidiol Modulates Cytokine Storm in Acute Respiratory Distress Syndrome Induced by Simulated Viral Infection Using Synthetic RNA

    FavorávelEstudo em Animais
  96. 2020

    Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?

    FavorávelMetanálise
  97. 2020

    Cannabinoids and the Coronavirus

    InconclusivoMetanálise
  98. 2020

    Cannabis for COVID-19: can cannabinoids quell the cytokine storm?

    FavorávelMetanálise
  99. 2020

    CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections

    FavorávelMetanálise
  100. 2020

    Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature

    FavorávelMetanáliseEquinácea
  101. 2020

    Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine

    InconclusivoMetanálise
  102. 2020

    COVID-19 and Cannabidiol (CBD)

    InconclusivoMetanálise
  103. 2020

    Debunking Cannabidiol as a Treatment for COVID-19: Time for the FDA to Adopt a Focused Deterrence Model?

    DesfavorávelMetanáliseCâncerDepressãoDoença de Alzheimer+1
  104. 2020

    Eucalyptol (1,8 cineole) from eucalyptus essential oil a potential inhibitor of COVID 19 corona virus infection by Molecular docking studies

    FavorávelEstudo Laboratorial
  105. 2020

    Evaluation of the Inhibitory Activities of COVID‐19 of Melaleuca cajuputi Oil Using Docking Simulation

    FavorávelEstudo Laboratorial
  106. 2020

    Genetic Liability to Cannabis Use Disorder and COVID-19 Hospitalization

    DesfavorávelMetanálise
  107. 2020

    Geranium and Lemon Essential Oils and Their Active Compounds Downregulate Angiotensin-Converting Enzyme 2 (ACE2), a SARS-CoV-2 Spike Receptor-Binding Domain, in Epithelial Cells

    FavorávelEstudo Laboratorial
  108. 2020

    In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues

    FavorávelEstudo Laboratorial
  109. 2020

    In search of preventive strategies: novel high-CBD Cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues

    InconclusivoEstudo Laboratorial
  110. 2020

    Letter to the Editor: Possible Drug–Drug Interactions Between Cannabinoids and Candidate COVID-19 Drugs

    InconclusivoMetanálise
  111. 2020

    Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients

    InconclusivoMetanálise
  112. 2020

    Protective effects of Δ 9 -tetrahydrocannabinol against enterotoxin-induced acute respiratory distress syndrome are mediated by modulation of microbiota

    FavorávelEstudo em AnimaisEstresseSíndrome do Desconforto Respiratório Agudo
  113. 2020

    The potential of cannabidiol in the COVID-19 pandemic

    FavorávelMetanálise
  114. 2020

    Therapeutic Cannabis and COVID-19: between opportunism and infoxication

    DesfavorávelMetanálise
  115. 2020

    Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies

    InconclusivoMetanáliseDorDependência QuímicaInflamação+6
  116. 2020

    Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated with Coronavirus Disease-2019

    InconclusivoMetanálise
  117. 2020

    Δ9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression

    FavorávelEstudo em Animais
  118. 2007

    Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells

    FavorávelEstudo LaboratorialInflamaçãoCanabinoides Sintéticos CP-xVirodamina (O-AEA)
  119. 1998

    Inhibition of cytokine production and arachidonic acid metabolism by eucalyptol (1.8-cineole) in human blood monocytes in vitro.

    FavorávelEstudo LaboratorialAsmaTosse

Continue por aqui

Perguntas frequentes

Quantos estudos sobre covid-19 estão indexados no acervo?
São 119 estudos, publicados entre 1998 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 67 · Estudo Laboratorial: 25 · Estudo em Animais: 11 · Ensaio Clínico: 10 · Ensaio Clínico Duplo-Cego: 5 · Metanálise Clínica: 1. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 85 favoráveis, 22 inconclusivos e 12 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. COVID-19 — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/condicao/covid-19/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). COVID-19 — estudos científicos sobre cannabis. https://cannabisindica.com.br/condicao/covid-19/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.